4.0
14. Okt. 2024
Aktueller Mitarbeiter, mehr als 10 Jahre
South San Francisco, CA
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Opportunity to learn High level of collaboration Focus on patients
Kontras
Upward mobility for IC's is and has been the Achille's heel of Genentech. It's glacial. Hyper-focus on AI/ML has come somewhat at the expense of letting the science speak. Everything feels rushed, which doesn't necessarily translate to developing great medicines. Uncharacteristically high amount of layoffs recently, heavily weighted towards IC's. Way too much mid-level management people who contribute little.